Scientists with The Cancer Genome Atlas (TCGA), a National Institutes of Health-funded project, have molecularly characterized two types of the second most common kidney cancer and classified several subtypes of the disease.
Nov 5, 2015
0
9
(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.
Oct 13, 2015
0
7
The first mouse model of an aggressive form of kidney cancer has identified an Achilles' heel in the disease that could lead to new treatment approaches in humans, according to a study by researchers at the School of Medicine.
May 12, 2015
2
85
A higher intake by postmenopausal women of the natural antioxidant lycopene, found in foods like tomatoes, watermelon and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer.
Mar 2, 2015
0
12
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was ...
Feb 24, 2015
0
5
Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma ...
Feb 24, 2015
0
9
A study led by researchers at the Institute for Molecular Medicine Finland FIMM and Faculty of Medicine, University of Helsinki and the Helsinki University Central Hospital Comprehensive Cancer Center, in close collaboration ...
Feb 9, 2015
1
46
In patients likely to have surgery, close, active monitoring of small renal tumors confined to the kidneys is associated with low rates of tumor growth or death, according to a study by a researcher at the Icahn School of ...
Jan 21, 2015
0
16
Singaporean researchers have developed a genetic test that can reliably identify different subtypes of a specific kind of kidney cancer. The test has the potential to improve treatment, as it can assess a patient's prognosis ...
Jan 14, 2015
0
19
Sunitinib, an agent approved for use in several cancers, provides unprecedented antitumor activity in thymic carcinoma, a rare but aggressive tumor of the thymus gland, according to a phase II clinical trial led by a researcher ...
Jan 12, 2015
0
16
